A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

AHS Cancer Control Alberta

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Solid Tumor

Lymphoma

Cancer

Brain Cancer

Treatments

Biological: 18F-FLT

Study type

Interventional

Funder types

Other

Identifiers

NCT01065805

DX-FLT-002

Details and patient eligibility

About

The Radiotracer 18F-FLT can non-invasively assess excessive cell growth in PET scan images. Tumour growth rate is a useful indicator of tumour aggression and response to treatment. Imaging and measuring the cell growth with 18F-FLT may be useful in monitoring response to anticancer treatment.

Full description

Clinical trial is a combined Phase I/II imaging, open label, single site study in patients with known or suspected carcinoma of the lung, breast, renal cell, pancreas or brain, and with gastrointestinal malignancies, neuroendocrine tumours, or lymphoma. One 18F-FLT PET scan will be performed in 10 Phase I patients, and pre-injection and post-imaging blood work and vital signs will be collected. Up to 5 18F-FLT PET scans will be performed in 170 Phase II patients.

Enrollment

94 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female greater than or equal to 16 years of age. If female of child-bearing potential and outside of the window of 10 days since the first day of last menstrual period, a negative pregnancy test is required.
Patients with known primary or suspected primary, recurrent or metastatic carcinoma of the lung, breast, renal cell, pancreas or brain (including GGM, oligodendrogliomas, and brain metastases from any primary tumour) and with gastrointestinal malignancies, neuroendocrine tumours (including carcinoid and islet cell malignancies, or lymphoma, with at least one lesion >1 cm in diameter.
Biochemical parameters as measured are required to be within 5 times the normal limits for age.
Able and willing to follow instruction and comply with the protocol
Provide written informed consent prior to participation in the study
Karnofsky Performance Scale Score 50-100

Exclusion criteria

Previous removal of entire tumour
Biochemical parameters as measured outside 5 times the normal limits for age
Unable or unwilling to follow instructions and comply with the protocol
Unable or unwilling to provide written informed consent prior to participation in the study
Karnofsky Performance Scale Score < 50
Nursing or pregnant females
Age less than 16 years